ARX788: A potential new treatment after T-DM1, Enhertu.
For some reason I can not post in "Articles of interest" section.
https://www.targetedonc.com/view/fda...BnbWFpbC5jb20=
http://ambrx.com/ambrx-presents-phas...cer-symposium/
ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
https://sci-hub.se/https://mct.aacrj....full-text.pdf
|